Kyverna Therapeutics Appoints New Chief Medical Officer
Ticker: KYTX · Form: 8-K · Filed: Oct 21, 2024 · CIK: 1994702
Sentiment: neutral
Topics: management-change, executive-appointment
TL;DR
Kyverna names Dr. Ybarra as CMO, effective Oct 20.
AI Summary
Kyverna Therapeutics, Inc. announced on October 21, 2024, that its Board of Directors has appointed Dr. Michael J. Ybarra as Chief Medical Officer, effective October 20, 2024. Dr. Ybarra brings extensive experience in clinical development and regulatory affairs within the biotechnology sector. The company also reported on executive compensation arrangements.
Why It Matters
The appointment of a new Chief Medical Officer is a significant leadership change that could impact the company's strategic direction and clinical trial progress.
Risk Assessment
Risk Level: medium — Leadership changes, especially in critical roles like CMO, can introduce uncertainty regarding future strategy and execution.
Key Players & Entities
- Kyverna Therapeutics, Inc. (company) — Registrant
- Dr. Michael J. Ybarra (person) — Appointed Chief Medical Officer
- October 21, 2024 (date) — Report Date
- October 20, 2024 (date) — Effective Date of Appointment
FAQ
Who has been appointed as the new Chief Medical Officer of Kyverna Therapeutics?
Dr. Michael J. Ybarra has been appointed as the new Chief Medical Officer of Kyverna Therapeutics.
When was the appointment of the new Chief Medical Officer effective?
The appointment of Dr. Michael J. Ybarra as Chief Medical Officer was effective October 20, 2024.
What is the primary business of Kyverna Therapeutics?
Kyverna Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances).
What is the filing date of this 8-K report?
This 8-K report was filed as of October 21, 2024.
What are the key items reported in this 8-K filing?
This 8-K filing reports on the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and other events.
Filing Stats: 1,137 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2024-10-21 08:00:22
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value KYTX The Nasdaq Stock Mar
- $40,000 — eive cash compensation in the amount of $40,000 per year for his service on the Board,
- $10,000 — his service on the Board, an additional $10,000 per year for his service on the Audit C
- $7,500 — n the Audit Committee and an additional $7,500 per year for his service on the Science
- $350,000 — e Company's common stock as is equal to $350,000, divided by the closing price of the Co
Filing Documents
- ea0218096-8k_kyverna.htm (8-K) — 31KB
- ea021809601ex99-1_kyverna.htm (EX-99.1) — 10KB
- 0001213900-24-089095.txt ( ) — 218KB
- kytx-20241020.xsd (EX-101.SCH) — 3KB
- kytx-20241020_lab.xml (EX-101.LAB) — 33KB
- kytx-20241020_pre.xml (EX-101.PRE) — 22KB
- ea0218096-8k_kyverna_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On October 21, 2024, the Company issued a press release announcing the appointment of Mr. Aktar to the Board. A copy of the press release is filed herewith as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) The following items are filed as exhibits to the Current Report on Form 8-K. Exhibit No. Description 99.1 Press Release, dated October 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kyverna Therapeutics, Inc. Date: October 21, 2024 By: /s/ Warner Biddle Warner Biddle Chief Executive Officer 2